Refine your results


In the Journals Plus

Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation

Stone RM, et al. N Engl J Med. 2017;doi:10.1056/NEJMoa1614359.
The addition of midostaurin to standard chemotherapy improved OS and EFS among patients with acute myeloid leukemia and FLT3 mutation, according to…
In the Journals Plus

Mood, quality of life worse in newly diagnosed incurable cancer

Nipp RD, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2016.71.3404.
Awareness of prognosis appeared associated with worse mood and quality of life among patients newly diagnosed with incurable cancer, study data
In the Journals Plus

Cost of hospital-based end-of-life care high for elderly with brain tumors

Dover LL, et al. JAMA Oncol. 2017;doi:10.1001/jamaoncol.2017.1624.
Hospital-based end-of-life care for elderly patients with malignant brain tumors is associated with up to $16,000 in expenses, according to a…
In the Journals Plus

Additional screening improves detection of new breast cancers following surgery

Cho N, et al. JAMA Oncol. 2017;doi:10.1001/jamaoncol.2017.1256.
The addition of MRI or ultrasonography to annual mammography…
In the Journals Plus

Lenvatinib improves OS in older patients with differentiated thyroid cancer

Brose MS, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2016.71.6472.
Lenvatinib demonstrated higher toxicity in older patients with radioiodine-refractory differentiated thyroid cancer, according to data from a phase
In the Journals PlusPerspective

First-line nivolumab fails to extend PFS in non–small cell lung cancer

Carbone DP, et al. N Engl J Med. 2017;doi:10.1056/NEJMoa1613493. Garon EB. N Engl J Med. 2017;doi:10.1056/NEJMe1705692.
Nivolumab did not result in longer PFS than platinum-based chemotherapy as first-line treatment for stage IV or recurrent non–small cell lung…
In the Journals Plus

Azacitidine-based combination may improve response rate in chronic myelomonocytic leukemia

Sekeres MA, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2015.66.2510.
Overall response rate improved with the addition of lenalidomide to azacitidine in patients with chronic myelomonocytic leukemia, according to…
In the Journals Plus

First-line cetuximab, bevacizumab show similar outcomes in colorectal cancer

Lieu CH and Messersmith WA. JAMA. 2017;doi:10.1001/jama.2017.6673.
Venook AP, et al. JAMA. 2017;doi:10.1001/jama.2017.7105.
The addition of cetuximab or bevacizumab to a first-line chemotherapy regimen demonstrated similar OS, PFS and response rates in patients with…
In the Journals Plus

Researchers define cancer risk in BRCA1/BRCA2 carriers

Kuchenbaecker KB, et al. JAMA. 2017;doi:10.1001/jama.2017.7112.
Women with BRCA1 mutations were more likely to develop breast cancer, ovarian cancer and contralateral breast cancer, and at earlier ages, than with…
In the Journals Plus

Tumor marker associated with poor ovarian cancer outcomes

Szender JB, et al. Gynecol Oncol. 2017;doi:10.1016/j.ygyno.2017.03.509.
Women with advanced ovarian cancer who expressed the tumor antigen
In the Journals Plus

Medicare beneficiaries with myeloma face 'substantial' financial burden for oral anticancer therapies

Olszewski AJ, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2017.72.2447.
The cost of oral anticancer medications presented a “substantial financial barrier” to Medicare beneficiaries with myeloma who did not
In the Journals Plus

Naldemedine improves opioid-induced constipation in patients with cancer

Katakami N, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2016.70.8453.
A 14-day treatment regimen with naldemedine improved opioid-induced constipation among patients with cancer, according to results of a phase 2b…
In the Journals Plus

Treatment improves OS in elderly patients with early-stage esophageal cancer

Moreno AC, et al. J Thorac Oncol. 2017;doi:10.1016/j.jtho.2017.04.004.
Elderly patients with early-stage esophageal cancer who received treatment achieved 5-year OS more often than those under observation, according to a…
In the Journals Plus

Men with prostate cancer willing to pay more for advanced biopsies

Ellimoottil C, et al. Urol Practice. 2017;doi:10.1016/j.urpr.2017.03.003.
Men with prostate cancer paid up to $2,000 out of health savings accounts for magnetic resonance imaging–transrectal ultrasound…
In the Journals Plus

Autologous stem cell transplant fails to improve outcomes in double-hit lymphoma

Landsburg DJ, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2017.72.2157.
Consolidative autologous hematopoietic stem cell transplantation did not improve 3-year RFS or OS in patients with double-hit lymphoma who achieved…
In the Journals Plus

Ferrous sulfate effective for pediatric iron-deficiency anemia

Powers JM, et al. JAMA. 2017;doi:10.1001/jama.2017.6846.
Infants and children aged 9 months to 4 years with nutritional iron-deficiency anemia had a greater increase in hemoglobin concentration at 12 weeks…
In the Journals Plus

FDA boxed warning reduces erythropoietin-stimulating agent use

Bian J, et al. J Clin Oncol. 2017;doi:10.1200/JCO.2017.72.6273.
A boxed warning advising of the risk for venous thromboembolism reduced use of erythropoietin-stimulating agents, study data showed.
In the Journals Plus

Pembrolizumab more effective after radiotherapy for NSCLC

Shaverdian N, et al. Lancet Oncol. 2017;doi:10.1016/S1470-2045(17)30380-7.
Pembrolizumab improved survival in patients with non–small cell lung cancer who previously underwent radiation therapy, according to a
In the Journals Plus

Guidelines: Stereotactic body radiation therapy an option for high-risk non–small cell lung cancer

Videtic GM, et al. Pract Radiat Oncol. 2017;doi:10.1016/j.prro.2017.04.014.
Patients with early-stage non–small cell lung cancer, particularly those whose tumors are inoperable and who have limited treatment options…
In the Journals PlusPerspective

CD4+ T cells rebound in HIV patients after chemotherapy

Henrich TJ, et al. J Infect Dis. 2017;doi:10.1093/infdis/jix265.
Despite a temporary — and in some cases “profound” — reduction in CD4+ T cells that were capable of harboring HIV, CD4+ T